On This Day in Health: February 8, 2013
On February 8, 2013, the United States Food and Drug Administration granted accelerated approval to pomalidomide, marketed as Pomalyst, for a defined group of patients with multiple myeloma. They had already received at least two previous therapies, including lenalidomide and bortezomib, and their disease had progressed during treatment or shortly after it ended. The decision addressed an especially difficult point in cancer care: what could be offered when established medicines no longer controlled the illness. It expanded the available treatment options, while leaving important questions about the size and durability of its clinical benefit to further investigation.
Multiple myeloma affects plasma cells, a type of white blood cell found in bone marrow. As abnormal cells accumulate, the disease can disrupt normal blood production and damage other parts of the body. Its course can include periods of response followed by relapse, requiring doctors to reconsider treatment as the illness changes. Pomalidomide is an oral immunomodulatory medicine related to thalidomide. Researchers investigated it because of its activity against myeloma and its effects on the immune system. The original approval focused on patients whose previous treatment history demonstrated a substantial unmet need, rather than on everyone with a new diagnosis of the disease.
Accelerated approval provided a route to earlier access based on a response measure that could reasonably predict a meaningful benefit. The original labeling explicitly stated that improvements in survival or symptoms had not yet been verified for the approval. That distinction matters when reading the anniversary historically. A regulator could authorize the medicine while still requiring additional work to establish the expected benefit. The drug also came with serious safety precautions, including a restricted distribution program intended to prevent exposure during pregnancy. Blood clots and effects on blood cell counts were among the risks considered in its prescribing framework. The decision combined a new option with an obligation to manage significant hazards.
Further research during 2013 examined pomalidomide with low-dose dexamethasone in patients with advanced disease. Those later findings belong to the continuing evidence history and should not be treated as knowledge already established on February 8. The milestone illustrates how oncology advances often develop through several stages: early evidence, a tightly defined authorization, additional trials, and subsequent assessment of benefits and risks. For patients whose disease has resisted other medicines, even another possible option can carry considerable significance. Yet an approval does not guarantee an individual response, cure the underlying cancer, or remove the burden of treatment. Its lasting importance is the expansion of choices alongside a continuing requirement for careful evaluation.
Earlier myeloma therapies could stop working as the disease returned or progressed. The original indication targeted patients with a particular history of prior treatment.
Pomalidomide belongs to the immunomodulatory class of medicines. Its development continued research into agents related to thalidomide, accompanied by stringent safety safeguards.
The February 8 decision used the accelerated approval pathway. Response evidence supported access before some direct clinical benefits had been verified.
Restricted distribution addressed the danger of exposure during pregnancy. The approval's safeguards were part of the milestone, alongside its potential benefits.
Additional trials helped develop the evidence after authorization. Their later results should remain distinct from what was established on the approval date.
The event reflects the recurring challenge of cancer that progresses after treatment. Expanding options still requires attention to uncertainty and individual outcomes.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.